title: Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance.
abstract: OBJECTIVE
  Insulin resistance is associated with serum C-reactive protein (CRP) levels. We aimed to evaluate the effect of bicalutamide on insulin resistance and serum CRP levels in non-obese polycystic ovarian syndrome (PCOS) patients.
  
  
  METHODS
  40 non-obese patients (BMI < or =25 kg/m2) with PCOS and, 40 age- and BMI-matched healthy women were studied. Patients received bicalutamide orally at the dose of 25 mg/day. Serum CRP levels were measured with immunometric assay. Homeostasis model assessment (HOMA-IR) index was used for insulin resistance.
  
  
  RESULTS
  Mean Ferriman-Gallwey score (FGS) (p = 0.001), insulin (p = 0.001), serum glucose (p = 0.001), prolactin (p < 0.003), total (p < 0.04) and free testosterone (p = 0.001) and free androgen index (FAI) levels (p = 0.001) of PCOS subjects were higher than in the control group. Mean HOMA-IR of PCOS patients was higher than in control subjects (2.43 +/- 1.2 and 0.94 +/- 0.37, p = 0.001). CRP levels in subjects with PCOS was also higher than in control subjects (4.27 +/- 1.33 and 0.98 +/- 0.19, p = 0.001). After bicalutamide treatment, FGS, free and total testosterone and FAI decreased (p = 0.001). HOMA-IR, prolactin and CRP levels did not show any statistical difference with bicalutamide treatment.
  
  
  CONCLUSIONS
  PCOS patients had insulin resistance and a high CRP level. Bicalutamide treatment did not influence insulin resistance and CRP level in PCOS, and this ineffectiveness of bicalutamide on CRP levels may be the result of insulin resistance and/or high prolactin levels at this time.
authors.affiliation: Department of Endocrinology, Dicle University School of Medicine, Diyarbakir, Turkey. mbahceci@dicle.edu.tr
authors.forename: Mithat
authors.initials: M
authors.lastname: Bahceci
authors.forename: Alpaslan
authors.initials: A
authors.lastname: Tuzcu
authors.forename: Naime
authors.initials: N
authors.lastname: Canoruc
authors.forename: Yekta
authors.initials: Y
authors.lastname: Tuzun
authors.forename: Veysel
authors.initials: V
authors.lastname: Kidir
authors.forename: Cetin
authors.initials: C
authors.lastname: Aslan
mesh_terms: D000328:Adult; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000813:Anilides / Q000627:therapeutic use*; D000886:Anthropometry; D001786:Blood Glucose / Q000378:metabolism; D002097:C-Reactive Protein / Q000378:metabolism*; D005260:Female; D006628:Hirsutism / Q000188:drug therapy* / Q000209:etiology; D006728:Hormones / Q000097:blood; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology*; D008055:Lipids / Q000097:blood; D009570:Nitriles; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications / Q000378:metabolism*; D014105:Tosyl Compounds
chemical_list: D000726:Androgen Antagonists; D000813:Anilides; D001786:Blood Glucose; D006728:Hormones; D008055:Lipids; D009570:Nitriles; D014105:Tosyl Compounds; D002097:C-Reactive Protein; C053541:bicalutamide